Product Comparison


 
NorthStar Rx 16714063102
Dr. Reddy's Laboratories 55111068852
Dr. Reddy's Laboratories 55111068507
Novartis 00078043561
Amgen Inc 55513073001
McKesson # 773134 835520 835519 625900 742959
Description Alendronate Sodium 10 mg Tablet Bottle 100 Tablets Zoledronic Acid 5 mg / 100 mL Ready to Use Intravenous Injection Infusion Bottle 100 mL Zoledronic Acid 4 mg / 5 mL Concentrate Intravenous Injection Single Use Vial 5 mL Reclast® Zoledronic Acid 5 mg / 100 mL Ready to Use Intravenous Injection Infusion Bottle 100 mL Xgeva® Denosumab 120 mg Subcutaneous Injection Single Dose Vial 1.7 mL
Manufacturer # 1671406310255111068852551110685070007804356155513073001
Brand    Reclast®Xgeva®
Manufacturer NorthStar RxDr. Reddy's LaboratoriesDr. Reddy's LaboratoriesNovartisAmgen Inc
Invoice ALENDRONATE SOD, TAB 10MG (100/BT)ZOLEDRONIC ACID, SDV 5MG 100MLZOLEDRONIC ACID, SDV 0.8MG/ML 5MLRECLAST, BTL INF 5MG/100ML 100MLXGEVA, SDV PF 120MG/1.7ML 1.7ML
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 12617592017226201723417666661611441
Container Type BottleInfusion BottleSingle Use VialInfusion BottleSingle Dose Vial
Dosage Form TabletInjectionInjectionInjectionInjection
Generic Drug Code 2168025026194762502629261
Generic Drug Name Alendronate SodiumZoledronic AcidZoledronic AcidZoledronic AcidDenosumab
NDC Number 16714-0631-0255111-0688-5255111-0685-0700078-0435-6155513-0730-01
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires Refrigeration
Strength 10 mg5 mg / 100 mL Ready to Use4 mg / 5 mL Concentrate5 mg / 100 mL Ready to Use120 mg
Type IntravenousIntravenousIntravenousSubcutaneous
UNSPSC Code 5118240651182415511824155118241551182428
Volume 100 Tablets100 mL5 mL100 mL1.7 mL
Application Bone Resorption InhibitorBone Resorption InhibitorBone Resorption InhibitorBone Resorption InhibitorBone Resorption Inhibitor
Country of Origin UnknownUnknownUnknownUnknownUnknown
Features and Benefits
  • Ready-to-use formulation
  • Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
  • The zoledronic acid injection infusion time must not be less than 15 minutes given over a constant infusion rate
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Infusion bottle with built-in plastic hanger
  • One bottle with 100 mL solution contains 5.330 mg of zoledronic acid monohydrate, equivalent to 5 mg zoledronic acid on an anhydrous basis
  • Inactive Ingredients: 4950 mg of mannitol, USP; and 30 mg of sodium citrate, USP
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Vials of zoledronic acid injection concentrate for infusion contain overfill allowing for the withdrawal of 5 mL of concentrate (equivalent to 4 mg zoledronic acid)
  • This concentrate should immediately be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP following proper aseptic technique, and administered to the patient by infusion
  • Do not store undiluted concentrate in a syringe, to avoid inadvertent injection
  • If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C-8°C (36°F-46°F)
  • Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of zoledronic acid injection should not exceed 4 mg and the duration of infusion should be no less than 15 minutes
  • Store at 25 degrees Celsius (77 degrees Fahrenheit); excursions permitted to 15 - 30 degrees Celsius (59 - 86 degrees Fahrenheit)
  • Reclast® is given as an infusion into a vein by a nurse or a doctor, and the infusion time must not be less than 15 minutes
  • Infusion solution is ready to use with Zoledronic Acid, Mannitol and Water
  • If refrigerated, allow the refrigerated solution to reach room temperature before administration
  • After opening the solution, it is stable for 24 hours at 2 - 8 degrees Celsius (36 - 46 degrees Fahrenheit)